%0 Journal Article
%T Pharmacotherapy of Systemic Sclerosis: focus on Bosentan
%A Kamyar Afshar
%A Ayana Boyd-King
%J Clinical Medicine : Therapeutics
%D 2009
%I 
%X Systemic sclerosis is manifested by the massive deposition of collagen within various organ systems. Endothelin-1 has taken a pivotal role as not only a potent vasoconstrictor, but also as a profibrotic intermediary. Bosentan is proving to be a viable therapeutic option in alleviating manifestations of systemic sclerosis other than pulmonary hypertension. There are many reports in the literature profiling bosentan¡¯s safety, efficacy and tolerability in patients. In addition, it has greatly improved patients¡¯ quality of life, reduced the number of hospitalizations and increased the time to clinical worsening of the disease. The clinical indications for use of bosentan in a wide array of patients has served as a valuable asset in the medical management of systemic sclerosis.
%K systemic sclerosis
%K bosentan
%K cutaneous fibrosis
%K pulmonary hypertension
%K Raynaud¡¯s phenomenon
%U http://www.la-press.com/pharmacotherapy-of-systemic-sclerosis-focus-on-bosentan-a1432